'Female viagra' could be approved next week by the FDA
Washington, June 12 (ANI): Next week, the FDA will vote on whether the female libido enhancing drug Flibanserin should be voted in or out. If in, it could mean a business of 2 billion dollars in US markets alone. The Food and Drug Administration will vote on what's being called 'female viagra', a drug that could be a boon to many women suffering from low sex drives across the globe but is still ensnared by controversy.
The pill is designed to treat a condition identified in an estimated 10 percent to 30 percent of women as hypoactive sexual desire disorder or HSDD - characterised by lack of sexual desire or fantasies, causing emotional distress, a rather vague diagnosis. The pill, however, comes with side effects, which include insomnia, nausea and dizziness. As always, women will need to decide whether the risks versus the benefits compared to other treatment alternatives are worth it for them.
